{"filing":{"accession_number":"0001140361-26-024560","cik":"0000320017","ticker":"LSTA","company_name":"LISATA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"ef20075787_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126024560/ef20075787_8k.htm"},"events":[{"id":4289,"run_id":3743,"accession_number":"0001140361-26-024560","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This disclosure concerns an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., extending key deadlines (tender offer commencement from June 1 to June 10, 2026, and the Outside Date from July 1 to July 17, 2026) and modifying payment obligations and waivers. The amendment directly relates to the ongoing merger transaction and materially affects its timing and conditions, making it a material M\u0026A activity event under Item 1.01.","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-06-09","items":[{"id":5405,"accession_number":"0001140361-26-024560","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This disclosure concerns an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., extending key deadlines (tender offer commencement from June 1 to June 10, 2026, and the Outside Date from July 1 to July 17, 2026) and modifying payment obligations and waivers. The amendment directly relates to the ongoing merger transaction and materially affects its timing and conditions, making it a material M\u0026A activity event under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:31:06.574632+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5405,"accession_number":"0001140361-26-024560","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This disclosure concerns an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., extending key deadlines (tender offer commencement from June 1 to June 10, 2026, and the Outside Date from July 1 to July 17, 2026) and modifying payment obligations and waivers. The amendment directly relates to the ongoing merger transaction and materially affects its timing and conditions, making it a material M\u0026A activity event under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:31:06.574632+00:00","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-06-09"}]}